Navigation Links
Advanced Cell Technology's Ability to Rescue Vision in Blind Rats,Noted in Scientific American

gn, or non-RPE cells into the eye is greatly reduced. Further, age-related diseases of the eye can potentially affect every human being, and ACTC is hopeful that its efforts will help serve a large and growing market.

Mr. Caldwell continued, "Our collaborations at OHSU will be important as we initiate toxicology and pharmacology studies to be managed by our newly appointed Chief Development Officer, Dr. Pedro Huertas. These studies will be important milestones toward our anticipated filing of the company's first Investigational New Drug application (IND) with the FDA."

About Advanced Cell Technology, Inc.

Advanced Cell Technology, Inc. is a biotechnology company applying stem cell technology in the emerging field of regenerative medicine. The company operates facilities in Alameda, California and Worcester, Massachusetts. For more information about the company visit www.advancedcell.com

Forward-Looking Statements

Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic
'"/>




Page: 1 2 3

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
3. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
4. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
5. Advanced Life Sciences to Host Conference Call to Discuss Data From Cethromycins First of Two Phase 3 Pneumonia Trials
6. Progenics and Wyeth Announce Positive Results from Three-Month Clinical-Extension Study of Subcutaneous Methylnaltrexone for the Treatment of Opioid-Induced Constipation in Patients with Advanced Illness
7. Advanced Cell Technology Develops First Human Embryonic Stem Cell Line without Destroying an Embryo
8. Neurologix Announces Publication of Landmark Gene Therapy Study Demonstrating Safety and Statistically Significant Improvement in Patients With Advanced Parkinsons Disease
9. Advanced Viral Research Corp. Announces Positive Preliminary Findings from Ongoing Phase II Dermatological Study
10. Clinical Data Reported on Vidaza in Hematologic Malignancies and Advanced Solid Tumors
11. Updated Study Results Reinforce Survival Benefit of Taxotere (Docetaxel) for Men with Advanced, Hormone-Resistant Prostate Cancer
Post Your Comments:
(Date:10/22/2014)... REDWOOD CITY, Calif. , Oct. 22, 2014 ... ) today announced that results from the  IAP310 ... and Pain Medicine (RAPM), a peer-reviewed journal ... placebo-controlled, Phase 3 trial evaluating the safety and ... sufentanil sublingual tablet system (SSTS), for the treatment ...
(Date:10/22/2014)... 22, 2014  Regulus Therapeutics Inc. (NASDAQ: ... leading the discovery and development of innovative ... has demonstrated human proof-of-concept with a microRNA ... RG-101, a wholly-owned, GalNac-conjugated anti-miR targeting microRNA-122 ... virus infection ("HCV").  Interim results from the ...
(Date:10/20/2014)... VIEW, Calif. , Oct. 20, 2014  PneumRx, ... of interventional pulmonology, today announced completion of enrollment in ... The RENEW Clinical Study is the FDA-approved IDE pivotal ... for severe emphysema. It was anticipated that ... in February 2013, would take until the end of ...
Breaking Medicine Technology:AcelRx Announces Publication of Zalviso Phase 3 Abdominal Trial Results 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 3A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 4A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 5A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 6A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 7A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 8PneumRx Completes RENEW Pivotal Trial Enrollment 2PneumRx Completes RENEW Pivotal Trial Enrollment 3
(Date:10/22/2014)... HealthDay Reporter , MONDAY, Oct. 20, 2014 (HealthDay ... for health workers treating Ebola patients, now requiring full body ... at all times. The U.S. Centers for Disease Control ... Dallas nurses contracted Ebola while caring for the first ... Duncan. Nina Pham is currently being treated for her infection ...
(Date:10/20/2014)... October 20, 2014 The newly updated ... source of thousands of facts, figures and forecasts on ... 68 medical sector forecast categories the Worldwide Medical ... regional and national views on the worldwide medical market ... The report gives you data for 2010-2019, covering each ...
(Date:10/20/2014)... Allegheny General Hospital’s (AGH) Cardiovascular Institute is offering ... a damaged mitral valve as the heart continues to ... Abbott Vascular , is designed to treat degenerative ... which the heart’s mitral valve leaflets fail to close ... left ventricle into the left atrium. The heart must ...
(Date:10/20/2014)... York, NY (PRWEB) October 20, 2014 ... based non-profit organization that helps New Yorkers living ... positive changes toward health, housing, recovery and self-sufficiency. ... have transformed the local community through their tireless ... Director, Marc Shapses , has been selected ...
(Date:10/20/2014)... ATLANTA, Ga. (PRWEB) October 20, 2014 ... networking and relationship-marketing firm, announced today that William ... been named the 2014 ISE® Luminary Leadership Award ... celebrates the achievements of an outstanding leader and ... stewardship and contributions in advancing the information security ...
Breaking Medicine News(10 mins):Health News:CDC Tightens Rules on Caring for Ebola Patients 2Health News:CDC Tightens Rules on Caring for Ebola Patients 3Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 2Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 3Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 4Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 2Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 3Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 2Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 3Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 2Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 3Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 4
... ... Jan Linhart reveals health benefits of orthodontics , ... New York, NY (Vocus) June 25, 2009 -- Dr. Jan Linhart, a ... but also to a patient’s health. , ,"While orthodontic procedures such as Invisalign and ...
... Verizon Business, Fully Managed Solution Provides Secure Foundation for ... PARIS, June 25 Invacare Corp., a ... has chosen Verizon Business to deploy and manage its ... IP solution effectively quadruples the bandwidth available to employees ...
... ... physicians, Jackson & Coker has helped sponsor several "medical brigades" visiting Honduras to perform ... ... Tapping the growing interest in medical volunteerism shown by many locum tenens physicians, Jackson ...
... Many parents worry about their child,s exposure to phthalates, the ... personal care products, children,s toys, and medical devices. Phthalate ... with negative changes in endocrine function. A new study ... examines the possibility that in utero phthalate exposure contributes ...
... , June 24 Siemens Healthcare ( ... Thomas Miller, Chief Executive Officer (CEO) for the Workflow & ... on Energy and Commerce, U.S. House of Representatives on the ... (Logo: http://www.newscom.com/cgi-bin/prnh/20070904/SIEMENSLOGO ) , ...
... recognized children,s health-care leader, may be faced with harsh decisions ... G. Rendell said today that Pennsylvania families should not have ... especially during hard economic times -- and urged the General ... the upcoming state budget. , , "The nation is ...
Cached Medicine News:Health News:Top Dentist Issues Opinion on Health Benefits of Cutting-Edge Orthodontics 2Health News:Verizon Private IP Quadruples Network Capacity for Invacare's European Operations 2Health News:Verizon Private IP Quadruples Network Capacity for Invacare's European Operations 3Health News:Jackson & Coker Sponsors Medical Missions 2Health News:Jackson & Coker Sponsors Medical Missions 3Health News:Siemens Healthcare Testifies on Healthcare Reform and Building a Healthier America 2Health News:Siemens Healthcare Testifies on Healthcare Reform and Building a Healthier America 3Health News:Pennsylvania Governor Rendell Urges General Assembly to Support Children's Health Insurance Program 2
This storage freezer, which is based on our premium freezer line, maintain red cells safely below regulatory standards at -86C (-123F). Recorder is standard for model 8627. Model 8627 is UL Listed, C...
... the precise requirements of blood banking ... Bank Equipment meets American Association of ... Cross (ANRC) and U.S. Food & ... freezers, and platelet incubators feature alarm ...
... Designed for the precise requirements ... Thermo Forma Blood Bank Equipment meets ... American National Red Cross (ANRC) and ... standards. Refrigerators, storage freezers, and platelet ...
... This refrigerator is specially ... of blood in standard ... Australian Standard AS3864 1997. ... air-cooled utilising CFC Free ...
Medicine Products: